// App-Quantinova.ai

: Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Researchers

Presenter

  • Alexander M Lesokhin

Principal Investigators

  • Suzanne Trudel

  • Adam D Cohen

  • Andrew Spencer

  • Peter A Forsberg

  • Jacob P Laubach

  • Sheeba K Thomas

  • Nizar J. Bahlis

  • Luciano J. Costa

  • Paula Rodriguez Otero

  • Maria-Victoria Mateos

  • Jesus G Berdeja

  • Rayan Kaedbey

  • Amrita Y. Krishnan

  • Rafael Fonseca

  • Voleak Choeurng

  • James Cooper

  • Teiko Sumiyoshi

  • Chihunt Wong

  • Simon J Harrison

Medical Centers

  • Mayo Clinic in Arizona, Phoenix, AZ

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada

  • Clinical Hematology, Alfred Health, Melbourne, Australia

  • Sarah Cannon Research Institute, Nashville, TN

  • Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Melbourne, Australia

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • Weill Cornell Medical College, New York, NY

  • City of Hope, Duarte, CA

  • Jewish General Hospital, McGill University, Montreal, Canada

  • University of Calgary, Calgary, Canada

  • O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL

  • The University of Texas MD Anderson Cancer Center, Houston, TX

  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Abramson Cancer Center and University of Pennsylvania, Philadelphia, PA

  • University of Colorado School of Medicine, Aurora, CO

  • Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain

Locations

  • United States

  • Spain

  • Canada

  • Australia

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Multiple Myeloma

  • Cytokine release syndrome

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved